BioNxt Solutions Inc. Advances Semaglutide Oral Dissolvable Film Program and Completes Debt Settlement

Vancouver, BC – BioNxt Solutions Inc. (CSE: BNXT) announced significant progress in its semaglutide oral dissolvable film (ODF) program, culminating in the successful completion of proof‑of‑concept trials at its wholly owned German subsidiary, Vektor Pharma TF GmbH. The company also disclosed a debt settlement agreement with an external creditor for an outstanding debt of $225,010.

1. Semaglutide ODF Program – Proof‑of‑Concept Success

  • Program Overview
    BioNxt is developing an oral dissolvable film (ODF) formulation of semaglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist currently marketed as an injectable drug for type 2 diabetes and obesity. The ODF platform aims to convert the drug into a patient‑friendly oral dosage form that could replace the injectable Ozempic.

  • Key Achievements

    • Completion of proof‑of‑concept (POC) studies at Vektor Pharma, demonstrating acceptable drug release, stability, and manufacturability.
    • Generation of first‑generation prototypes of semaglutide ODFs, which met pre‑defined pharmacokinetic and physicochemical criteria.
    • Evaluation of multiple proprietary film‑forming platforms, with one platform showing superior performance.

  • Strategic Implications
    The success of the ODF POC positions BioNxt to pursue a potential oral semaglutide product that could capture a large market in diabetes and obesity treatment, leveraging the company’s expertise in natural compound discovery and formulation technology.

2. Debt Settlement Agreement

  • Transaction Details

    • On 12 September 2025, BioNxt entered into a debt settlement agreement with an arm‑of‑the‑bank creditor.
    • The agreement covered an aggregate outstanding debt of $225,010 related to services rendered to BioNxt.
    • The settlement was executed in full satisfaction of the debt, with no further financial obligation to the creditor.

  • Impact on Financial Position
    The settlement reduces short‑term liabilities and improves the company’s balance sheet. It also frees up capital that can be allocated to ongoing R&D initiatives, including the semaglutide ODF program and other pipeline projects.

3. Market Context

  • BioNxt’s focus on natural compound discovery for oncology and neurodegenerative diseases aligns with growing demand for novel therapeutics in these therapeutic areas.
  • The company’s market capitalization is approximately $81 million CAD (as of 16 September 2025), with a closing share price of $0.70 CAD.
  • The 52‑week high and low for the stock are $1.10 CAD and $0.19 CAD, respectively, reflecting volatility but also potential upside if the ODF program progresses successfully.

4. Outlook

BioNxt will continue to advance its semaglutide ODF platform toward regulatory submission and commercialization. Concurrently, the company will monitor opportunities to apply its formulation expertise to other therapeutic indications, including its existing pipeline in cancer and neurodegeneration. The recent debt settlement improves liquidity, enabling further investment in research and development.